Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals is a clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat antibiotic-resistant bacterial infections. The company leverages proprietary bacteriophage technology to engineer targeted treatments that address infectious diseases caused by multidrug-resistant pathogens. Its pipeline includes AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 for Pseudomonas aeruginosa infections, and AP-PA03 for pneumonia caused by resistant gram-negative bacteria.

The company maintains a research collaboration with Merck Sharp & Dohme Corp. to develop synthetic bacteriophage candidates targeting additional undisclosed infectious disease agents, representing a potential revenue or co-development stream. As a clinical-stage entity, the company does not currently generate product revenues from marketed therapeutics.

Armata operates with approximately 60 full-time employees from its Los Angeles headquarters. The company is incorporated in Washington and operates as a subsidiary of Innoviva, Inc. Its research and development activities are concentrated in the United States, with operations focused on advancing its bacteriophage candidates through clinical trials.